Serum Resistin Levels and Coronary Heart Disease Severity from a Network Meta-Analysis

A 2026 network meta-analysis by Yicheng Ling, aggregating data from 26 studies with 9,169 subjects, quantifies the relationship between serum resistin levels and coronary heart disease severity. The analysis includes standardized mean differences and SUCRA rankings for disease stages from healthy controls to acute myocardial infarction. The dataset is derived from a systematic review registered with PROSPERO.

Use Cases

• Training models to stratify coronary heart disease severity based on biomarker levels mentioned in the description.
• Validating the inflammatory biomarker hypothesis in cardiovascular disease progression based on the reported SMD values.
• Benchmarking new biomarker assays against the established resistin severity gradient from the meta-analysis.

Strengths

• Includes data from 26 studies with a total of 9,169 subjects.
• Provides standardized mean differences (SMD) and SUCRA rankings for four distinct disease severity stages.
• Systematic review methodology is documented with a PROSPERO registration.

Limitations

• The dataset is a 77.7 KB PDF summary; the underlying raw tabular data is not provided.
• The original meta-analysis reported substantial heterogeneity (I²=95.8%) and evidence of publication bias.
• Column-level documentation and sample data are unavailable, requiring manual extraction from the PDF.

Provenance

Source

Yicheng Ling via figshare.

Collection Method

Systematic review and network meta-analysis of published studies.

Time Range

Studies included up to December 2025.

Freshness

Last updated 2026-05-28.